Company intelligence / Profile preview

Sichuan Gooddoctor Panxi Pharmaceutical

Xichang, Sichuan, Chinahys.cn ↗

Ownership: Private
Development stage: Commercial

Overview

Sichuan Gooddoctor Panxi Pharmaceutical has an approved drug (SanQi LongXueJie Capsule) for cardiovascular diseases in China. Other pipeline assets are in Phase 1 or Phase 2 clinical trials targeting conditions such as radiation oral mucositis, inflammatory bowel disease, chronic heart failure, and wound healing. The company is recognized as a national high-tech enterprise with significant R&D capabilities including a postdoctoral research station and key laboratories.

Therapeutic areas: OncologyCardiovascularGastroenterologyOther
Modalities: Small moleculeRecombinant polypeptideHerbal medicine
Industry: Biotech

Drug pipeline

4 assets

kangfuxin

Approved

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Sichuan Gooddoctor Panxi Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sichuan Gooddoctor Panxi Pharmaceutical.

Explore the full profile